Diabetic Drugs

12345
Across
  1. 2. inhibit Na+/glucose symporter SGLT-2 in nephrons
  2. 4. Decreases gluconeogenesis by upregulating AMP activity and inhibiting glycerol-3-P-DH, contraindicated for compromised kidney function and no
Down
  1. 1. Release insulin granules by blocking K+ efflux
  2. 3. Inhibit DPP-IV to increase insulin secretion and reduce glucagon secretion
  3. 5. Activates GLP-1 receptors to increase insulin secretion from beta pancreatic cells and suppress glucagon secretion